Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|61|3|769-775

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.3, 2015-03, pp. : 769-775

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

By  

HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. : 1793-1797

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1004-1012

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1004-1012

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C‐related cirrhosis, genotype 4

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 674-679

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

By  

HEPATOLOGY, Vol. 64, Iss. 4, 2016-10 ,pp. : 1049-1056

John Wiley & Sons Inc

Access to resources Recommend Favorite